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Evaluation of Early Complications Related
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Peter C. Austin, PHD,* Zhongliang Chen, MD, MSC,* Judy Hardy, RN,* Jack V. Tu, MD, PHD,*‡
for the Investigators of the Ontario ICD Database
Toronto, Hamilton, London, Ottawa, Kingston, Newmarket, and Scarborough, Ontario, Canada
Objectives This study examined the predictors of early complications after defibrillator implantation.
Background Although implantable cardioverter-defibrillators are widely used, predictors of procedural complications and the
consequences of these events have not been determined.
Methods In a prospective, multicenter, population-based clinical outcomes registry of all newly implanted defibrillator pa-
tients at 18 centers in Ontario, Canada, we examined 45-day complications and all-cause mortality from Febru-
ary 2007 to May 2009. Complications were determined longitudinally and were categorized as direct implant-
related or indirect events.
Results Among 3,340 patients (mean age 63.8  12.5 years, 78.5% men), major complications occurred in 4.1% of
de novo procedures. Compared with those undergoing a single-chamber device, implantation of a cardiac
resynchronization defibrillator (adjusted hazard ratio [HR]: 2.17, 95% confidence interval [CI]: 1.38 to 3.43,
p  0.001) or dual-chamber device (adjusted HR: 1.82, 95% CI: 1.19 to 2.79, p  0.006) was associated with
increased risk of major complications. Major complications were increased in women (adjusted HR: 1.49, 95%
CI: 1.02 to 2.16, p  0.037) and when left ventricular end-systolic dimension exceeded 45 mm (adjusted HR:
1.54, 95% CI: 1.08 to 2.20, p  0.018). Major complications (excluding death) occurring early after defibrillator
implantation were associated with increased adjusted risk of subsequent death up to 180 days after defibrillator
implant (adjusted HR: 3.70, 95% CI: 1.64 to 8.33, p  0.002). Direct implant-related complications were associ-
ated with increased risk of early death (adjusted HR: 24.89, p  0.01), whereas indirect clinical complications
conferred increased risk of near-term death (adjusted HR: 12.35, p  0.001) after defibrillator implantation.
Conclusions Complications after de novo defibrillator implantation were strongly associated with device type. Major complica-
tions were associated with increased risk of mortality. (J Am Coll Cardiol 2010;55:774–82) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.029c
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February 23, 2010:774–82 Complications of ICDseft ventricular systolic dysfunction and selected patients with
rior cardiac arrest or sustained ventricular tachycardia (1–4).
n response to the broadening indication for these devices, the
se of ICDs has increased to include patients who are asymp-
omatic but could be at increased risk of sudden cardiac death.
Implantation of a cardioverter-defibrillator entails a surgical
rocedure with the attendant potential for complications.
ittle is known about the rates and predictors of complications
fter ICD implantation. Indeed, patients who undergo defi-
rillator implantation have significant cardiac conditions and
oncardiac comorbidities and may therefore be at higher risk of
eveloping complications from the procedure than has been
emonstrated in randomized trials (5). Furthermore, the types
f devices being used currently also differ from those used in
he clinical trials, with greater use of dual-chamber devices or
ardiac resynchronization defibrillators. Complications of ICD
mplantation are not only important from the standpoint of
atient care, but they also add significantly to length of hospital
tay, increase health care costs, and influence the defibrillator’s
ost-effectiveness (6).
In this study, we examined the outcomes of patients
ndergoing defibrillator implantation in the Ontario ICD
atabase, a population-based, prospective registry of pa-
ients undergoing device implantation. In de novo defibril-
ator recipients undergoing the procedure for primary or
econdary prevention, we examined the frequency of these
arly complications and their predictors. We hypothesized
hat the burden of complications after defibrillator implan-
ation would be predicted by both patient and device
haracteristics.
ethods
atients. We examined patients undergoing de novo implan-
ation of a cardioverter defibrillator (e.g., for primary or
econdary prevention indication) in the Ontario ICD Database
etween February 2007 and May 2009. The design and
ethodology of the Ontario ICD Database have been pub-
ished elsewhere (7). Briefly, this project is an ongoing pro-
pective clinical registry of all patients (age 16 years) under-
oing defibrillator implantation in Ontario, Canada, which has
een mandated by the Ontario Ministry of Health and
ong-Term Care. Patient data are collected upon initial
valuation, at the time of defibrillator implant, and at each
ollow-up visit in the device clinic. As a prescribed entity, we
ere able to collect data on all patients in this registry without
nformed consent, and therefore all patients had their data
ntered into the database without participation bias (8).
ata sources. Details of the primary data collection process
or the Ontario ICD Database have been described previously
7). Briefly, data in the ICD database were collected by the
lectrophysiologist and a trained research coordinator at defi-
rillator implantation centers, who entered the data into a
ecure, firewall- and password-protected Web-based registry at
he Institute for Clinical Evaluative Sciences. We collected
ata on patient characteristics, indication for the defibrillator, oomorbidities, left ventricular ejec-
ion fraction, and implant-related
ata. We also collected clinical and
evice-related events occurring in
ollow-up, with data entered at the
mplanting hospital or peripheral
mbulatory device clinics. Data
uality was continually assessed by:
) regular review and correspon-
ence with study sites to ensure
ccuracy of coded data; 2) auto-
ated range checks, notification to study sites of uncoded data
lements followed by recoding; 3) logic checks of key data
lements including dates of all events; and 4) ongoing random
ite audits for reliability and data collection mechanisms.
Deaths were identified by clinical follow-up at routine
efibrillator clinic visits and via the Registered Persons
atabase linked using the patient’s unique encrypted health
ard number. Vital status data were available for all study
atients. Ethics approval was obtained from the Sunny-
rook Health Sciences Centre before study initiation. A
omplete list of participating defibrillator implant and
ollow-up sites is shown in Online Appendix 1.
omplications. At defibrillator clinic visits after device
mplantation, patients were routinely evaluated for any
evice-related complications that occurred within 45 days of
he procedure using a standard checklist. We selected 45
ays for determination of complications for several reasons:
) it was temporally close to the device implant date; 2) all
ites conducted an initial post-implant clinic visit within 45
ays; and 3) most early complications occurred during this
eriod, thus maximizing the potential capture of events (9).
ecause the date of the initial post-implant clinic visit could
ary, we cross-referenced the recorded dates of complica-
ions from subsequent clinic visits and counted those events
ccurring temporally within 45 days following implantation.
hese complications were categorized as major or minor
Table 1), based on the consensus of electrophysiologists
rom all participating hospitals, and was guided by a
revious report (10). In general, major complications were
istinguished from minor events by the need for an opera-
ion to revise the lead or device or for therapeutic relief.
linical complications were considered to be major if
ospitalization or substantive parenteral therapy were re-
uired. Major complications were subclassified as direct
implant-related) or indirect (clinical disease) events. Major
omplications included death unless otherwise specified.
atients were deemed to have had “any complication” if they
xperienced a major or a minor complication.
actors associated with complications. The variables
onsidered in the univariate analysis were determined after
eview of the literature and included age, sex, prior ventric-
lar tachycardia, and primary disease etiology (e.g., isch-
mic, nonischemic cardiomyopathy, or other conditions
uch as congenital heart disease or hypertrophic cardiomy-
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
CRT-D  cardiac
resynchronization therapy
defibrillator
ICD  implantable
cardioverter-defibrillatorpathy). Cardiac factors included prior myocardial infarc-
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Complications of ICDs February 23, 2010:774–82ion, revascularization procedure, heart failure, New York
eart Association functional class, pre-existing pacemaker
ystem, and atrial fibrillation. Noncardiac factors included
eneral laboratory measures (e.g., serum creatinine concen-
ration, estimated glomerular filtration rate, serum sodium,
emoglobin) and comorbidities. Medications were also ex-
mined, including angiotensin-converting enzyme inhibitor or
ngiotensin-receptor blocker, beta-adrenoreceptor antagonists,
oop diuretic, antiplatelet or anticoagulant drug, amiodarone,
nd class IC or other class III antiarrhythmic drugs. Diagnostic
nvestigations included QRS interval duration (140 ms vs.
140 ms), left ventricular ejection fraction (20%, 21% to
5%, or 35%), left ventricular dimension in end-systole or
nd-diastole, and left atrial size. We also examined the type of
CD implanted (e.g., dual-chamber, cardiac resynchronization
herapy defibrillator device [CRT-D], or single-chamber de-
ice), active versus passive fixation, and single versus dual coil
ight ventricular lead.
tatistical analysis. We performed descriptive analyses of
atients undergoing ICD implant for primary or secondary
revention indications. We then performed univariate Cox
egression analysis to determine predictors of time to
omplication after ICD implant. Potential predictors with
 0.25 on univariate analysis were included in the
ultiple regression model using a stepwise approach, and
ajor Versus Minor ComplicationsTable 1 Major Versus Minor Complications
Major Complications* Minor Complications
Mechanical complications
Lead dislodgment with
repositioning
Coronary venous dissection
Lead repositioning Subclavian vein thrombosis
Lead replacement Renal insufficiency
Lead extraction Incisional infection
Device problem—setscrew Peripheral nerve injury
Device problem—pocket revision Nonsuperficial venous thrombus
Myocardial perforation Lead dislodgement not repositioned
Pericardial tamponade Diaphragmatic stimulation
Pneumothorax/hemothorax Site pain
Pocket infection Lead fracture not requiring intervention
Skin erosion Pocket hematoma
Pocket hematoma requiring
intervention
Clinical complications
Pulmonary edema
Electrical storm
Cardiogenic shock
Post implant myocardial
infarction
Hypotension requiring
resuscitation
Sepsis
Stroke
Noncerebral embolus
Death
Major nonfatal complications exclude death.redictors with p  0.05 in the multivariable model were detained. The final model selection was based on clinical and
tatistical significance. All models included age irrespective
f statistical significance, because of the potential of this
ariable to account for complications.
We determined the association of major complications
xcluding death (e.g., major nondeath complications) with
ortality employing complication status as a time-varying
ovariate in Cox regression analysis. In the time-varying
odel, patients were considered complication-free until a
ajor complication occurred, at which time they were
eclassified. Complications occurring more than 45 days
fter implantation were not included in the determination of
xposure status. We determined the association of major
omplications with death occurring up to 180 days after
efibrillator implant adjusted for age, sex, and ICD type.
he preceding analyses were also repeated for minor com-
lications. Continuous data are presented as mean  SD
nd compared using Student t test. Categorical variables
ere compared using the chi-square test, Fisher exact test,
r the Mantel-Haenszel test for trend. Exact 95% confi-
ence intervals (CIs) were determined using published
ethods. All analyses were performed using SAS software,
ersion 9.1 (SAS Institute, Cary, North Carolina).
esults
atient characteristics. Among a total of 4,217 referrals for
e novo ICD from February 2007 to May 15, 2009, patients
ere excluded because they refused the procedure (n  183),
nderwent the procedure within 45 days of the last follow-up
ate (n  273), or did not meet criteria for the device (n 
21). The final study cohort consisted of 3,340 patients, and
heir characteristics are shown in Table 2 according to primary
r secondary prevention status. Follow-up data for mortality
nd complications were available for all study patients. The
ajority of patients had ischemic heart disease, and nearly
wo-thirds of device implants were for primary prevention
ndications.
omplication rates. A total of 172 primary (7.4%) and 76
econdary (7.6%) prevention patients experienced any com-
lication. There was no significant difference in overall
omplication rates by primary or secondary prevention
ndications. Major complications occurred in 90 patients
3.8%) undergoing primary prevention ICD and 48 (4.8%)
ho underwent secondary prevention device implantation.
inor complications occurred in 125 (5.3%) and 45 (4.5%)
f those undergoing primary or secondary prevention defi-
rillator implantation. Only a small proportion of compli-
ations occurred in-hospital, at rates of 0.5% for major,
.5% for minor, and 0.8% for any complication.
nivariate predictors of complications. Univariate predic-
ors of major and minor complications are shown in Online
ppendixes 2 and 3, respectively. The most significant factor
ssociated with complications was the type of device im-
lanted, with high risk in those undergoing dual-chamber
evice and the highest risk for CRT-D (Fig. 1). The number
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February 23, 2010:774–82 Complications of ICDsf new leads implanted was also a significant predictor of major
omplications, with hazard ratios of 1.78 (95% CI: 1.21 to
.63) for 2 leads and 2.17 (95% CI: 1.38 to 3.40) for 3 leads,
elative to 1 lead (p  0.004 and p  0.001, respectively).
azard ratios (HRs) for minor complications were 1.51 (95%
I: 1.06 to 2.15, p  0.023) and 2.42 (95% CI: 1.64 to 3.56,
 0.001) for 2 and 3 leads, respectively. The risk of major
omplications was also increased in women (HR: 1.57, 95%
I: 1.09 to 2.26) and with New York Heart Association
unctional class III to IV (HR: 1.47, 95% CI: 1.04 to 2.08).
Minor complications were more likely to occur in women
HR: 1.40, 95% CI: 1.00 to 1.96), those with New York
eart Association functional class III to IV (HR: 1.73, 95%
I: 1.27 to 2.35), or those with nonischemic dilated
ardiomyopathy (HR: 2.21, 95% CI: 1.35 to 3.61, when
ompared with ischemic). Univariate analyses for primary
revention device were similar to those for de novo im-
lants; however, anticoagulant drug use was a significant
redictor of complications in the former group. Among
hose taking oral anticoagulants, aspirin or clopidogrel, the
Rs were 2.15 (95% CI: 1.08 to 4.30, p  0.030) for major
nd 1.85 (95% CI: 1.06 to 3.24, p  0.031) for minor
omplications.
ultivariable predictors of complications. Multivariable
redictors of complications among de novo ICD recipients
re shown in Table 3. Age was not significantly associated
ith major or minor complications and therefore, these
azard ratios are not shown. Dual-chamber and CRT-D
efibrillators were the most significant predictors of major
omplications, with 1.5- and 2-fold increase in risk,
espectively, compared with those receiving a single-
hamber device. Increased left ventricular end-diastolic
imension 45 mm was associated with a 1.5-fold increase
n risk. Women were more likely to develop major compli-
ations than men (Table 3). Minor complications were also
ncreased in those receiving dual-chamber and CRT-D
evices, and in those with nonischemic cardiac disease
tiologies (Table 3).
In the subset of patients undergoing primary prevention
CD implantation, device type had an even greater effect on
ajor complications with a 2.6- and 3.2-fold risk for
ual-chamber and CRT-D, respectively (Table 4). Prior use
f antiplatelet agents or anticoagulants increased the risk of
ajor complications, as did the use of class IC or class III
ntiarrhythmic drugs other than amiodarone (Table 4).
ypes of complications. The complications occurring with
ighest frequency are shown in Table 5. In some cases,
ultiple complications occurred in the same patient. The most
requent major complications were lead-related, followed by
ocket infection, electrical storm, and pulmonary edema re-
uiring hospitalization. The majority of lead replacements (76
f 94 81%) and lead extractions (21 of 23 91%) were not
receded by a lead recall. Incisional infections and pocket
ematomas that did not require an operative procedure (med-cally managed) were the most common minor complications. sssociation of complications with death. Patients who
xperienced a major complication (excluding death) had a
ignificantly higher rate of subsequent mortality than those
ithout a major complication within the first 45 days after
CD implantation. Crude mortality rates were 2.2% versus
.5% at 45 days (p 0.036), 2.9% versus 1.2% at 90 days (p
.09), and 5.1% versus 1.8% at 180 days (p 0.018) for those
ith versus those without a major nonfatal complication within
he first 45 days. Adjusted mortality was significantly increased
n those who experienced a major complication within 45 days,
ut not in those with minor complications (Table 6).
In further analyses, we found that mortality rates were
igher among those who experienced any major complica-
ion within the 45-day perioperative period compared with
hose without complications (Fig. 2). The HR for direct
mplant-related complications adjusted for age, sex, and
CD type was 24.89 (95% CI: 2.11 to 294.26) in the first 45
ays following defibrillator implantation (p  0.01). Pa-
ients with indirect clinical complications (excluding death)
ccurring within 45 days of ICD implant were associated
ith substantially higher mortality rates when compared
ith those patients without early complications (Fig. 2).
he adjusted HR for indirect clinical complications was
2.35 (95% CI: 4.74 to 32.18) in the 180-day follow-up
eriod after defibrillator implantation (p  0.001).
iscussion
n this population-based registry, we found that periopera-
ive complications were not infrequent, with 4.1% experi-
ncing major complications after de novo defibrillator im-
lantation. The predominant factor associated with both
ajor and minor complications was the type of device
mplanted, with increased risk in those receiving dual-
hamber devices and the highest risk after cardiac resyn-
hronization defibrillator implantation. Women and those
ith an enlarged left ventricular chamber size were at
ncreased risk of complications after de novo defibrillator
mplantation. Use of anticoagulants or antiplatelet agents
nd antiarrhythmic drugs also predicted increased risk of
omplications among those undergoing a primary preven-
ion defibrillator. The occurrence of a major, early compli-
ation was associated with an increased risk of death with a
- to 4-fold risk up to 6 months after device implantation.
tratified by the type of major complication, we found that
oth direct implant-related and indirect clinical complica-
ions were associated with significantly increased risk of
eath.
Previous studies have reported on selected complications
fter defibrillator implantation. A German ICD registry
eported rates of specific complications and found that
ocket hematoma, chronic pain, and lead and device dis-
odgements leading to operative revisions were the most
ommon events (11). However, participation in this registry
as voluntary with considerable losses to follow-up (11). Aingle-center study spanning a decade of defibrillator im-
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Complications of ICDs February 23, 2010:774–82Baseline CharacteristicsTable 2 Baseline Characteristics
Primary Prevention Secondary Prevention p Value
n 2,341 999
Age, yrs 63.9  11.9 63.6  13.9 0.44
Men 1,834 (78.3) 789 (79.0) 0.68
Cardiac disease etiology
Ischemic 1,561 (66.7) 677 (67.8) 0.001
Cardiomyopathy 650 (27.8) 144 (14.4)
Other 130 (5.6) 178 (17.8)
Prior MI 1,364 (58.3) 601 (60.2) 0.31
MI within 40 days 61 (2.6) 142 (14.8) 0.001
Prior heart failure 1,594 (68.1) 371 (37.1) 0.001
NYHA functional class
I 601 (25.7) 542 (54.3) 0.001
II 950 (40.6) 302 (30.2)
III 743 (31.7) 137 (13.7)
IV 47 (2.0) 18 (1.8)
Prior PCI or CABG surgery 1,100 (47.0) 405 (40.5) 0.001
Atrial fibrillation 690 (29.5) 299 (29.9) 0.79
Diabetes 814 (34.8) 270 (27.0) 0.001
Hypertension 1,251 (53.4) 551 (55.2) 0.36
Stroke or TIA 294 (12.6) 95 (9.5) 0.012
PVD 225 (9.6) 91 (9.1) 0.65
COPD 366 (15.6) 139 (13.9) 0.20
Medications
ACE inhibitor 1,701 (72.7) 654 (65.5) 0.001
Angiotensin-receptor blocker 414 (17.7) 113 (11.3) 0.001
Beta-adrenoreceptor antagonist 2,015 (86.1) 835 (83.6) 0.047
Furosemide 1,483 (63.3) 369 (36.9) 0.001
Digoxin 612 (26.1) 104 (10.4) 0.001
Amiodarone 273 (11.7) 372 (37.2) 0.001
Other class III or 1C AAD 9 (0.4) 16 (1.6) 0.001
HMG-CoA reductase inhibitor 1,679 (71.7) 689 (69.0) 0.11
Aspirin 1,402 (59.9) 704 (70.5) 0.001
Clopidogrel 427 (18.2) 291 (29.1) 0.001
Oral anticoagulant 725 (31.0) 183 (18.3) 0.001
Systolic blood pressure, mm Hg 121  20 124  20 0.003
Weight, kg 83.8  25.0 83.6  19.1 0.82
Sodium, mmol/l 138.8  3.5 138.5  3.3 0.055
Hemoglobin, g/dl 13.6  1.7 12.7  1.9 0.001
Creatinine, mg/dl 1.26  0.78 1.23  0.70 0.20
Creatinine, mol/l 111.6  68.6 108.3  61.6 0.20
eGFR, ml/min/1.73 m2 68.7  30.6 71.4  28.2 0.017
ECG QRS duration, ms 132.8  36.0 122.6  35.6 0.001
LVEF by RNA or echocardiography 27.0  9.5 37.2  14.0 0.001
LVEDD, mm 62.0  11.2 56.8  9.7 0.001
LVESD, mm 51.0  12.6 43.7  11.6 0.001
Left atrial size, mm 46.0  9.9 42.8  8.7 0.001
Type of device implanted
Single-chamber 1,017 (43.4) 453 (45.3) 0.001
Dual-chamber 624 (26.7) 461 (46.1)
CRT-ICD 700 (29.9) 85 (8.5)
RV lead characteristics*
Passive fixation 140 (6.0) 50 (5.0) 0.29
Active fixation 2,198 (93.9) 938 (93.9)
Continued on next page
p
c
d
r
(
i
l
r
r
m
I
1
r
m
t
t
u
e
d
o
c
t
c
e
c
m
e
f
I
h
p
p
t
u
a
o
t
i
d
d
a
p
r
b
a
a
w
w
o
c
i
T
i
l
i
d
t
t
t
c
d
d
percuta
779JACC Vol. 55, No. 8, 2010 Lee et al.
February 23, 2010:774–82 Complications of ICDslantations reported that 10% of patients experienced a
omplication within 30 days and that biventricular and
ual-chamber devices were associated with more lead-
elated complications (12). However, this study was small
440 patients) and was limited in the ability to define
ndependent predictors of major complications (12). A
arger multicenter study reported that lead- and pocket-
elated complications occurred in 2.1% and 1.8% of cases,
espectively, but predictors of these events were not deter-
ined (13). The National Cardiovascular Data Registry
CD Registry reported in-hospital complication rates of
.3% for major and 3.6% for any complication (14); that
egistry differed from our study because reporting was not
andatory from all hospitals (15,16), in-hospital complica-
ions were the primary events counted, and lead complica-
ions were not included (14).
Previous studies evaluating defibrillator complications
sing large administrative databases have reported different
vent rates and predictors. Using Medicare administrative
atabases, 90-day complications were reported to have
ccurred in 14.2% of patients (17). Many of the major
omplications in this study overlapped with ours; however,
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Figure 1 Rates of 45-Day Complications by Defibrillator Type
Rates of major (top) and minor (bottom) 45-day complications by defibrillator
type. CRT-D  cardiac resynchronization therapy defibrillator; ICD  implant-
able cardioverter-defibrillator.
ContinuedTable 2 Continued
Characteristic Primary Prev
Number of RV coils†
Single coil 100 (4.3
Dual coil 2,237 (95
Values are n (%) or mean SD. *Right ventricular lead data available
coil data available for 2,337 primary and 985 secondary prevention p
AAD  antiarrhythmic drug; ACE  angiotensin-converting enzyme;
disease; CRT-ICD  cardiac resynchronization therapy defibrillator; eGFR
coenzyme A; LVEDD left ventricular end-diastolic dimension; LVEF le
MImyocardial infarction; NYHA New York Heart Association; PCI
radionuclide angiogram; TIA transient ischemic attack.the predictors differed and were predominantly noncardiac
omorbidities (17). Our study differed because we consid-
red an early post-procedural time window, which reflects
omplications related to device implantation, and further-
ore, we used clinically obtained data on predictors and
vents. Importantly, another study of Medicare beneficiaries
ound that in-hospital complications occurred in 10.8% of
CD recipients and led to significant increases in length of
ospital stay and costs compared with an uncomplicated
rocedure (18).
Our study is novel because the data were collected in a
rospective, population-based registry, with detailed longi-
udinal follow-up. We also examined outcomes bimodally,
sing a combination of both clinical device and passive
dministrative data-based follow-up, allowing for capture
f important outcomes including death. Our study adds
o the current literature in several ways. First, we exam-
ned complications that occurred in the early post-
efibrillator implant period including events following
ischarge (19). Second, this registry was mandated by the
dministrator of health care services in Ontario, and
articipation from all defibrillator implanting centers was
equired. Thus, our study was not subject to volunteer
ias, and we were able to study all patients irrespective of
ge. Finally, a wide array of potential clinical predictors
nd major and minor complications, including death,
ere systematically evaluated.
The potential mechanisms of the mortality association
ith major complications may be a direct or indirect result
f complications. The early mortality effects of major
omplications may be the direct consequence of a mechan-
cal procedure-related event (e.g., myocardial perforation).
hese mechanical complications were potentially related to
ncreasing procedural complexity with greater number of
eads implanted, and anticoagulation or antiplatelet agents
n the subgroup of patients undergoing primary prevention
efibrillators. The latter is particularly relevant given the
endency of some to implant defibrillators without discon-
inuation of oral anticoagulants combined with bridge
herapy (20,21). The mortality effects of indirect clinical
omplications began early and were maintained up to 180
ays following implantation, likely reflecting progressive
isease of the underlying cardiovascular disease substrate
Secondary Prevention p Value
27 (2.7) 0.035
958 (95.9)
8 primary and 988 secondary prevention patients. †Right ventricular
.
coronary artery bypass graft; COPD  chronic obstructive pulmonary
ated glomerular filtration rate; HMG-CoA  3-hydroxy-3-methylglutaryl
icular ejection fraction; LVESD left ventricular end-systolic dimension;
neous coronary intervention; PVD peripheral vascular disease; RNAention
)
.6)
for 2,33
atients
CABG 
 estim
ft ventrhat predisposed to a higher a priori risk of death. The
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Complications of ICDs February 23, 2010:774–82ssociation of enlarged left ventricular chamber size with
omplications may reflect altered biventricular and atrial
eometry, which confer both an increased propensity to
oth mechanical complications and increased clinical
isk. We have previously shown that heart failure events
ontribute significantly to reduced survival (22), and
rogressive heart failure substantially increases the risk of
eath among defibrillator recipients who have experi-
nced an appropriate therapy (23), signifying the impor-
ance of this condition on outcomes after device implan-
ation. High mortality rates have been reported in those
ith electrical storm (24,25), but the data are conflicting
26), and prior studies have not examined this in the
Multivariable Predictors of Complications in All(e.g., P mary an Secondary Preven )Table 3 Multivariable Predictors of Complic(e.g., Primary and Secondary Preve
Major complications*
Women
Secondary vs. primary prevention
Nonischemic vs. ischemic CM
Other cardiac disease vs. ischemic CM
Anticoagulation, aspirin or clopidogrel vs. none
Amiodarone vs. none
Class 1 or other class 3 AAD vs. none
LVESD 45 mm vs. 45 mm
Dual vs. single-chamber ICD
CRT-D vs. single-chamber
Minor complications*
Women
Secondary vs. primary prevention
Nonischemic vs. ischemic CM
Other cardiac disease vs. ischemic CM
Anticoagulation, aspirin, or clopidogrel vs. none
Dual- vs. single-chamber ICD
CRT-D vs. single-chamber
*Age not significant in multivariable model; hazard ratio for age not s
CI  confidence interval; CM  cardiomyopathy; CRT-D  cardiac resy
other abbreviations as in Table 2.
Multivariable Predictors of Complications in PrimTable 4 Multivariable Predictors of Complic
Major complications*
Women
Anticoagulation, aspirin or clopidogrel vs. none
Amiodarone vs. none
Class 1 or other class 3 AAD vs. none
Dual-chamber vs. single-chamber ICD
CRT-D vs. single-chamber
Minor complications*
Women
Nonischemic vs. ischemic CM
Other cardiac disease vs. ischemic CM
Dual- vs. single-chamber ICD
CRT-D vs. single-chamber*Age not significant in multivariable model; hazard ratio for age not shown.
Abbreviations as in Tables 2 and 3.ontext of complications arising in the perioperative
hase. The use of antiarrhythmic drugs reflects underly-
ng abnormalities in the electrical substrate, which may
ave conferred an increase in clinical complications
ecause of more severe structural disease.
Few studies have systematically examined the predictors
f major and minor complications according to indication
or the ICD using multivariable analysis. Our study suggests
hat early complications of ICD implantation are not
nfrequent and suggest an increased risk of death if major
omplications occurred. These data also suggest that com-
lications are driven in part by the underlying sickness of the
atient, and these factors may be attenuated by optimization
s in All ICDs
)
azard Ratio 95% CI p Value
1.49 1.02–2.16 0.037
1.45 0.97–2.16 0.071
1.54 0.89–2.69 0.12
1.40 0.86–2.28 0.18
1.51 0.92–2.47 0.10
0.91 0.58–1.41 0.67
3.26 1.02–10.43 0.046
1.54 1.08–2.20 0.018
1.82 1.19–2.79 0.006
2.17 1.38–3.43 0.001
1.28 0.91–1.80 0.16
0.92 0.64–1.32 0.64
1.94 1.16–3.22 0.011
1.76 1.11–2.79 0.015
1.43 0.92–2.21 0.11
1.57 1.07–2.30 0.021
2.13 1.44–3.16 0.001
ization therapy defibrillator; ICD  implantable cardioverter-defibrillator;
Prevention ICDss in Primary Prevention ICDs
zard Ratio 95% CI p Value
1.27 0.80–2.04 0.31
2.33 1.15–4.71 0.018
0.43 0.19–1.00 0.051
7.39 1.78–30.63 0.006
2.68 1.48–4.85 0.001
3.29 1.86–5.81 0.001
1.28 0.91–1.80 0.16
1.94 1.17–3.24 0.011
1.75 1.11–2.76 0.017
1.55 1.06–2.27 0.023
2.17 1.47–3.20 0.001ICDsation
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February 23, 2010:774–82 Complications of ICDsf the underlying cardiac disease before defibrillator implan-
ation. This may be most relevant for patients who are
eferred for CRT-D, who are those at greatest risk of
omplications driven by heart failure and their underlying
ardiac status. Although near-term death was infrequent in
efibrillator recipients, the association should also be exam-
ned in other cohorts because of the importance of this
utcome. Minor complications remain clinically important
ecause these events may influence quality of life, but
urther data are needed to determine the degree of this
ssociation. Finally, it should carefully be considered
hether patients require more complex, multilead devices as
pposed to simpler devices with fewer leads.
tudy limitations. Although we identified a number of
redictors of complications, we could not determine the
ausal pathway by which these factors exerted their effects.
t is possible that these effects may be complex, exerting
heir effects on subcomplications by a multitude of mecha-
isms. We did not examine intraoperative factors such as
rocedure duration; however, it would likely have been
onger with implantation of more complex devices. We did
Frequent Major and Minor ComplicationsTable 5 Frequent Major and Minor Complica
Numb
Occurr
Major complications*
Lead replacement 94
Lead repositioning 67
Pocket infection requiring debridement 40
Electrical storm 33
Lead dislodgement with repositioning 29
Lead extraction 23
Pulmonary edema 24
Myocardial perforation 15
Pneumothorax/hemothorax 13
Post-implant myocardial infarction 8
Sepsis 8
Cardiogenic shock 7
Minor complications*
Incisional infection 38
Pocket hematoma 41
Lead dislodgement not repositioned† 28
Subclavian vein thrombosis 8
*Only complications with frequency 5 are shown. †Lead dislodgeme
djusted Hazard Ratios for Mortality According toresence of a Major Nondeath Complicationithin 45 Days
Table 6
Adjusted Hazard Ratios for M rtality According to
Presence of a Major Nondeath Complication
Within 45 Days
Hazard
Ratio 95% CI p Value
Any major complication excluding death
Adjusted for age and sex 3.79 1.69–8.51 0.001
Adjusted for age, sex, and ICD type 3.70 1.64–8.33 0.002
Minor complication
Adjusted for age and sex 1.12 0.35–3.62 0.85
Adjusted for age, sex, and ICD type 1.08 0.33–3.50 0.90bbreviations as in Table 3.ot examine those undergoing replacement devices, for
hom the predictors and consequences of complications
ay differ substantially from these findings. Lastly, our data
uggested an association of major complications with mor-
ality, but could not determine whether the complication
as causally related to death.
onclusions
significant proportion of patients undergoing de novo
mplantation of cardioverter defibrillators experienced com-
lications. The complexity of device implanted, female sex,
nd enlarged left ventricular dimension were significant
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Figure 2 Mortality Rates for Defibrillator
Recipients With or Without Complications
Mortality rates at 45, 90, and 180 days for defibrillator recipients with clinical
complications, any complication (implant-related or clinical), and no complica-
tions. The p values for comparison with no complication group are shown.
Any  any complication (major or minor); compl  complication.
Number of
Patients Affected
% Patients
With Complication
90 2.7
67 2.0
32 1.0
29 0.9
28 0.8
23 0.7
21 0.6
14 0.4
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Complications of ICDs February 23, 2010:774–82redictors of major complications. Because direct implant-
elated complications and indirect disease-related major
erioperative events were associated with an increased risk
f death, further evaluations of early defibrillator complica-
ions, their potential effects on mortality, and preventative
trategies are needed.
eprint requests and correspondence: Dr. Douglas S. Lee,
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APPENDIX
or a list of participating hospitals and investigators in the Ontario ICD
atabase and the univariate predictors of major and minor complications,
lease see the online version of this article.
